Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US

By afschroeder • August 5, 2025

Pei PP, Jones M, Hu R, Chen W, Sax PE, Pandya A, Gandhi M, Eron JJ, Currier JS, Wilkin TJ, Reddy KP, Qoshe L, Hyle EP, Freedberg KA. Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the US. Clin Infect Dis. 2025 Aug 4:ciaf428. doi: 10.1093/cid/ciaf428. Epub ahead of print. PMID: 40757869.

Tags: clinical trials, HIV, Implementation, Infectious Diseases, long-acting antiretrovirals, Publications, resistance

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson[...]

A New Approach to In Vivo Transformation of Killer T cells

Rodriguez N, Hofmann C, Yang OO, Gelbart WM. A New Approach to In Vivo Transformation of Killer T cells. J Mol Biol. 2025 Aug 1:169369.[...]

A peer-educator driven approach for sampling populations at increased mpox risk in the Democratic Republic of the Congo: Implications for surveillance and response

Merritt S, Halbrook M, Anta Y, Mukadi PK, Hasivirwe Vakaniaki E, Bodisa-Matamu T, Lunyanga L, Kacita C, Kompany JP, Makangara-Cigolo JC, Kenye M, Kavira S,[...]